Hybrigenics Services will significantly strengthen its worldwide leadership as the reference Y2H service provider to screen functional protein interactions

Paris, 01 July 2013 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, announces the acquisition by Hybrigenics Services, its subsidiary specialized in protein interactions, of the yeast two-hybrid (Y2H) activities of Dualsystems Biotech, a privately owned Swiss company based in Schlieren near Zurich. Financial terms are not disclosed and will not involve the issuance of any Hybrigenics shares.

This operation will boost Hybrigenics Services’ commercial reach in German-speaking territories, Eastern Europe and China, in addition to Hybrigenics Services’ existing strong positions in North America and Western Europe (outside Germany). The customers for Y2H services are research laboratories involved in all life sciences, either from academia or industry, which need to know with which other proteins their protein of interest interacts to achieve its biological functions. Hybrigenics Services delivers for each protein such an “address book” of its main “partners”, ranked by scientific relevance.

Hybrigenics Services will also get exclusive ownership of a patented Y2H screening technology specifically suited to membrane proteins. Moreover, Hybrigenics Services’ and Dualsystems Biotech’s catalogues of genomic and cDNA libraries will nicely complement each other to offer the widest range of human organs, animal and plant species and microbiological organisms to which the Y2H screening technology can be applied.

“This operation is both a business and technology opportunity which fits precisely well with our current expert leadership position in the field of functional proteomics.” said Remi Delansorne, Hybrigenics’ CEO.

About Hybrigenics Services
Hybrigenics Services (www.hybrigenics-services.com), a fully-owned subsidiary of Hybrigenics, is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform.

About Hybrigenics
Hybrigenics (www.hybrigenics.com) is a bio-pharmaceutical company listed (ALHYG) on Alternext (NYSE-Euronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative cancerous or non-cancerous diseases.

Hybrigenics’ current development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol has shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastastic castrate-resistant prostate cancer in combination with Taxotere®, which is the current gold-standard chemotherapeutic treatment for this indication. Oral inecalcitol is currently being tested in chronic lymphocytic leukemia patients.

Hybrigenics has a research collaboration with Servier on deubiquitinating enzymes and their inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases. Hybrigenics continues to build on its pioneer research position in the field of ubiquitin-specific proteases by exploring their role in other areas of particular relevance, such as inflammation and virology. « back to overview